Slomiany B L, Slomiany A
Research Center, University of Medicine and Dentistry of New Jersey, Newark, USA.
Scand J Gastroenterol. 2000 Nov;35(11):1131-6. doi: 10.1080/003655200750056583.
Disturbances in nitric oxide generation and the release of a vasoactive peptide, endothelin-1 (ET-1), are well recognized early events in pathogenesis of NSAID-induced gastropathy. In this study using phosphoramidon, a potent inhibitor of endothelin-converting enzyme-1 (ECE-1), we investigated the influence of ET-1 on the expression of constitutive (cNOS) and inducible nitric oxide synthase (NOS-2) during gastric mucosal injury caused by indomethacin.
The experiments were conducted with groups of rats pretreated intragastrically with phosphoramidon (10, 20, and 40 mg/kg) or vehicle, followed 30 min later by an intragastric dose of indomethacin (60 mg/kg). The animals were killed 4 h later and their mucosal tissue subjected to macroscopic damage assessment and biochemical measurements.
In the absence of phosphoramidon, indomethacin caused extensive multiple hemorrhagic lesions of glandular mucosa, accompanied by a 29.9-fold increase in epithelial cell apoptosis, a 13.3-fold increase in NOS-2 and a 5.5-fold decline in the activity of cNOS, while the mucosal expression of ECE-1 activity increased 4-fold and the level of ET-1 showed a 4.8-fold increase. Pretreatment with phosphoramidon produced dose-dependent reduction in the extent of mucosal damage caused by indomethacin, accompanied by a significant recovery in the expression of cNOS, and a marked decline in ECE-1, epithelial cell apoptosis and the mucosal level of ET-1. Phosphoramidon, however, had no effect on the indomethacin-induced increase in the mucosal expression of NOS-2.
The results suggest that suppression of ET-1 generation counters the mucosal drop in cNOS and the extent of gastric mucosal damage caused by indomethacin, but has no effect on the mucosal responses associated with up-regulation of NOS-2 expression. Hence, only cNOS plays a role in the protection of gastric mucosa against damage by NSAIDs.
一氧化氮生成紊乱以及血管活性肽内皮素-1(ET-1)的释放,是公认的非甾体抗炎药(NSAID)诱导的胃病发病机制中的早期事件。在本研究中,我们使用内皮素转换酶-1(ECE-1)的强效抑制剂磷酰胺素,研究了ET-1对吲哚美辛引起的胃黏膜损伤过程中组成型一氧化氮合酶(cNOS)和诱导型一氧化氮合酶(NOS-2)表达的影响。
实验用磷酰胺素(10、20和40mg/kg)或赋形剂对大鼠进行胃内预处理,30分钟后给予胃内剂量的吲哚美辛(60mg/kg)。4小时后处死动物,对其黏膜组织进行宏观损伤评估和生化测量。
在没有磷酰胺素的情况下,吲哚美辛导致腺性黏膜广泛多处出血性病变,伴有上皮细胞凋亡增加29.9倍、NOS-2增加13.3倍以及cNOS活性下降5.5倍,而黏膜ECE-1活性增加4倍,ET-1水平增加4.8倍。磷酰胺素预处理使吲哚美辛引起的黏膜损伤程度呈剂量依赖性降低,同时cNOS表达显著恢复,ECE-1、上皮细胞凋亡和黏膜ET-1水平显著下降。然而,磷酰胺素对吲哚美辛诱导的黏膜NOS-2表达增加没有影响。
结果表明,抑制ET-1生成可对抗cNOS的黏膜下降以及吲哚美辛引起的胃黏膜损伤程度,但对与NOS-2表达上调相关的黏膜反应没有影响。因此,只有cNOS在保护胃黏膜免受NSAIDs损伤中起作用。